Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* indication for treatment with Gilenya according label~* treatment with Gilenya intended~* no contraindications for the treatment with Gilanya~* all safety-aspects have been fullfilled~* age between 18 and 60 years~* written consent is given~Exclusion Criteria:~* relapse during the last 30 days befor randomization~* steroids within 30 days before randomization~* heart rhythm disturbance~* new or currently changed dose (last 4 weeks) of bata-blockers, calcium antagonists, antidepressants or antiarrhythmics~* diabetes mellitus~* polyneuropathy~* missing consent~* pregnancy~* lactation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Gilenya (Type: EXPERIMENTAL): Autonomic testing during first dose adminstration of Gilenya.

Based on this trial design, predict the completion outcome and termination type (if applicable).